- Home
- SEVN vs TRVI Comparison
SEVN vs TRVI Comparison
Compare SEVN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- TRVI
- Stock Information
- Founded
- SEVN 1986
- TRVI 2011
- Country
- SEVN United States
- TRVI United States
- Employees
- SEVN N/A
- TRVI N/A
- Industry
- SEVN Real Estate Investment Trusts
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- TRVI Health Care
- Exchange
- SEVN Nasdaq
- TRVI Nasdaq
- Market Cap
- SEVN 198.5M
- TRVI 211.4M
- IPO Year
- SEVN N/A
- TRVI 2019
- Fundamental
- Price
- SEVN $13.54
- TRVI $4.65
- Analyst Decision
- SEVN Strong Buy
- TRVI Strong Buy
- Analyst Count
- SEVN 3
- TRVI 8
- Target Price
- SEVN $14.50
- TRVI $9.31
- AVG Volume (30 Days)
- SEVN 53.5K
- TRVI 4.0M
- Earning Date
- SEVN 10-28-2024
- TRVI 11-06-2024
- Dividend Yield
- SEVN 10.28%
- TRVI N/A
- EPS Growth
- SEVN N/A
- TRVI N/A
- EPS
- SEVN 1.28
- TRVI N/A
- Revenue
- SEVN $30,401,000.00
- TRVI N/A
- Revenue This Year
- SEVN N/A
- TRVI N/A
- Revenue Next Year
- SEVN N/A
- TRVI N/A
- P/E Ratio
- SEVN $10.48
- TRVI N/A
- Revenue Growth
- SEVN N/A
- TRVI N/A
- 52 Week Low
- SEVN $11.23
- TRVI $1.26
- 52 Week High
- SEVN $14.66
- TRVI $4.60
- Technical
- Relative Strength Index (RSI)
- SEVN 54.60
- TRVI 75.02
- Support Level
- SEVN $13.33
- TRVI $2.36
- Resistance Level
- SEVN $13.80
- TRVI $4.60
- Average True Range (ATR)
- SEVN 0.34
- TRVI 0.33
- MACD
- SEVN 0.05
- TRVI 0.21
- Stochastic Oscillator
- SEVN 60.47
- TRVI 92.46
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.